DefiniGEN has significant experience in using CRISPR/Cas9 gene editing technology to manipulate the genome of iPSC to generate disease models, and we can also offer an accomplished end-to-end approach to gene editing of other cell lines or primary cells to help support your drug discovery research. Our expertise can help design the guide RNA’s (gRNA) in silico for maximum efficiency, then optimise the electroporation of the cell line in question to best establish ideal conditions for the gene edit. Our team then methodically sequence a number of clones to confirm the precise genetic manipulation has been successful. We offer a collaborative partnership with our clients to deliver models in a timely and efficient manner.
To help you generate your particular disease models, we offer gene editing services to knock out a target gene or knock in a disease specific mutation. We will deliver high-quality edited iPSC, from your disease- or patient specific donor lines. The cells will be edited to your bespoke specification using our CRISPR/Cas9 technology platform.
Contact us today so we can get started on your project.